Hold Parameters for Allopurinol
Allopurinol should be held immediately if any signs of hypersensitivity reaction develop, including rash, fever, or systemic symptoms, as these may herald life-threatening severe cutaneous adverse reactions (SCARs) with a 25-30% mortality rate 1.
Absolute Indications to Hold Allopurinol
Hypersensitivity Reactions (IMMEDIATE DISCONTINUATION)
- Any new rash - this is the most critical warning sign
- Fever with rash
- Eosinophilia
- Worsening renal function in conjunction with rash
- Signs of Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN)
- Drug rash with eosinophilia and systemic symptoms (DRESS)
The development of allopurinol hypersensitivity syndrome (AHS) carries a mortality rate of 25-30% 1. This severe reaction includes erythematous desquamative skin rash, fever, hepatitis, eosinophilia, and deteriorating renal function 2. Once any cutaneous manifestation appears, allopurinol must be stopped immediately and never restarted 3, 4.
Severe Hepatotoxicity
- Significant elevation in liver enzymes with systemic symptoms
- Clinical hepatitis
Relative Contraindications Requiring Dose Adjustment (Not Complete Hold)
Renal Impairment
Rather than holding allopurinol entirely, dose adjustment is required based on creatinine clearance 5:
- CrCl 10-20 mL/min: Maximum 200 mg/day
- CrCl <10 mL/min: Maximum 100 mg/day
- CrCl <3 mL/min: Extend dosing interval beyond daily
The rationale is that oxypurinol (allopurinol's active metabolite) accumulates in renal failure, increasing the risk of SCARs 1, 2. However, complete discontinuation is not necessary—dose reduction is the appropriate response 1.
Acute Gout Flare
Do NOT hold allopurinol during an acute gout flare if the patient is already taking it 6. Stopping and restarting urate-lowering therapy causes serum urate fluctuations that can perpetuate flares. Continue allopurinol and treat the acute flare separately with anti-inflammatory agents.
Clinical Scenarios Where Allopurinol Should NOT Be Started (But Not Held if Already On)
Asymptomatic Hyperuricemia
- Allopurinol is NOT indicated for asymptomatic hyperuricemia 6, 5, 7
- The FDA label explicitly states: "THIS IS NOT AN INNOCUOUS DRUG. IT IS NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA" 5
- The 2020 ACR guidelines conditionally recommend against initiating ULT in asymptomatic hyperuricemia 6
However, if a patient is already established on allopurinol with good control, this is not a reason to discontinue.
Key Risk Factors Requiring Enhanced Monitoring (Not Automatic Hold)
Patients at highest risk for AHS who require vigilant monitoring include:
- Elderly patients (mean age 69 years in AHS cases) 3, 8
- Chinese ethnicity (96% of AHS cases) 3
- Renal impairment (86% of AHS cases had baseline renal dysfunction) 3, 8
- Starting dose >100 mg/day or >1.5 mg per unit eGFR 9, 8
In these high-risk patients, start at ≤100 mg/day (or ≤50 mg/day in CKD stage ≥3) and titrate slowly 6, 9. This is dose adjustment, not holding the medication.
Common Pitfalls to Avoid
- Do not hold allopurinol during acute flares - this worsens disease control
- Do not confuse dose adjustment with discontinuation - renal impairment requires lower doses, not complete cessation
- Do not ignore early rash - any new rash mandates immediate discontinuation given the high mortality of SCARs
- Do not restart allopurinol after hypersensitivity - switch to febuxostat or other alternatives 1
Drug Interactions Requiring Caution (Not Automatic Hold)
While not absolute hold parameters, be aware of:
- Concurrent use with strong P-glycoprotein/CYP3A4 inhibitors when also on colchicine prophylaxis 1
- Thiazide or loop diuretics (consider switching if possible) 1
These require monitoring and potential medication adjustments rather than holding allopurinol.